JP2006509830A - 癌予防用ハイブリッド細胞ワクチンの調製および投与 - Google Patents

癌予防用ハイブリッド細胞ワクチンの調製および投与 Download PDF

Info

Publication number
JP2006509830A
JP2006509830A JP2004563716A JP2004563716A JP2006509830A JP 2006509830 A JP2006509830 A JP 2006509830A JP 2004563716 A JP2004563716 A JP 2004563716A JP 2004563716 A JP2004563716 A JP 2004563716A JP 2006509830 A JP2006509830 A JP 2006509830A
Authority
JP
Japan
Prior art keywords
cell
cells
dendritic
cancer
precancerous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004563716A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006509830A5 (https=
Inventor
典也 大野
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2006509830A publication Critical patent/JP2006509830A/ja
Publication of JP2006509830A5 publication Critical patent/JP2006509830A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/35—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2004563716A 2002-12-16 2003-12-16 癌予防用ハイブリッド細胞ワクチンの調製および投与 Pending JP2006509830A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/320,779 US20040115224A1 (en) 2002-12-16 2002-12-16 Preparation and administration of hybrid cell vaccines for the prevention of cancer
PCT/US2003/040284 WO2004057968A1 (en) 2002-12-16 2003-12-16 Preparation and administration of hybrid cell vaccines for the prevention of cancer

Publications (2)

Publication Number Publication Date
JP2006509830A true JP2006509830A (ja) 2006-03-23
JP2006509830A5 JP2006509830A5 (https=) 2007-02-08

Family

ID=32506941

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004563716A Pending JP2006509830A (ja) 2002-12-16 2003-12-16 癌予防用ハイブリッド細胞ワクチンの調製および投与

Country Status (7)

Country Link
US (1) US20040115224A1 (https=)
EP (1) EP1583424A4 (https=)
JP (1) JP2006509830A (https=)
AU (1) AU2003301023A1 (https=)
CA (1) CA2508209A1 (https=)
IL (1) IL169124A0 (https=)
WO (1) WO2004057968A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002225990B2 (en) * 2000-10-20 2007-07-19 Tsuneya Ohno Fusion cells and cytokine compositions for treatment of disease
US20050180951A1 (en) * 2004-02-12 2005-08-18 Tsuneya Ohno Combined immunotherapy of fusion cells and interleukin-12 for treatment of cancer
AU2005218638A1 (en) * 2004-03-02 2005-09-15 Donald W. Kufe Methods and compositions for hybrid cell vaccines for the treatment and prevention of cancer
WO2008097559A2 (en) 2007-02-06 2008-08-14 Brandeis University Manipulation of fluids and reactions in microfluidic systems
US8592221B2 (en) 2007-04-19 2013-11-26 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
JP5721428B2 (ja) * 2007-04-27 2015-05-20 バヴァリアン・ノルディック・アクティーゼルスカブ マクロファージ−コロニー刺激因子（ｍ−ｃｓｆ）による樹状細胞発生の誘導
US9695397B2 (en) 2008-10-01 2017-07-04 Immunovative Therapies Ltd. Th1 vaccination priming for active immunotherapy
WO2010111231A1 (en) 2009-03-23 2010-09-30 Raindance Technologies, Inc. Manipulation of microfluidic droplets
JP2022542745A (ja) * 2019-05-27 2022-10-07 錦高キャピタル株式会社 樹状細胞ベースの癌ワクチン及びその調製方法
WO2022108306A1 (ko) * 2020-11-17 2022-05-27 성균관대학교산학협력단 인터류킨-33을 처리하여 면역원성이 향상된 cd103+ fcgr3+ 수지상세포의 제조방법 및 상기 수지상세포를 포함하는 면역항암치료용 약학적 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001059073A2 (en) * 2000-02-11 2001-08-16 Dana-Farber Cancer Institute, Inc. Cytotoxic t lymphocytes activated by dendritic cell hybrids
JP2001526622A (ja) * 1994-07-18 2001-12-18 シドニー キンメル キャンサー センター インビボでの腫瘍細胞免疫を高めるための組成物および方法
JP2002501377A (ja) * 1997-04-15 2002-01-15 ダナ−ファーバー キャンサー インスティテュート インク． 樹状細胞ハイブリッド

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3519404A1 (de) * 1984-06-07 1985-12-12 Marginvest S.A. Holding, Luxemburg/Luxembourg Verfahren zur herstellung eines absorptions- und adsorptionsmittels, sowie nach diesem verfahren hergestelltes absorptions- und adsorptionsmittel
US20020041868A1 (en) * 1997-04-15 2002-04-11 Charles Nicolette Cell fusions and methods of making and using the same
AU2002225990B2 (en) * 2000-10-20 2007-07-19 Tsuneya Ohno Fusion cells and cytokine compositions for treatment of disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001526622A (ja) * 1994-07-18 2001-12-18 シドニー キンメル キャンサー センター インビボでの腫瘍細胞免疫を高めるための組成物および方法
JP2002501377A (ja) * 1997-04-15 2002-01-15 ダナ−ファーバー キャンサー インスティテュート インク． 樹状細胞ハイブリッド
WO2001059073A2 (en) * 2000-02-11 2001-08-16 Dana-Farber Cancer Institute, Inc. Cytotoxic t lymphocytes activated by dendritic cell hybrids

Also Published As

Publication number Publication date
WO2004057968A1 (en) 2004-07-15
EP1583424A1 (en) 2005-10-12
IL169124A0 (en) 2007-07-04
US20040115224A1 (en) 2004-06-17
EP1583424A4 (en) 2006-12-27
CA2508209A1 (en) 2004-07-15
AU2003301023A1 (en) 2004-07-22

Similar Documents

Publication Publication Date Title
Lambert et al. Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity
Mukherjee et al. Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer
Panelli et al. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100
RU2313365C2 (ru) Фармацевтическая композиция для индукции иммунной реакции у человека
AU2015209277B2 (en) Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
Wu et al. Identification of EGFRvIII-derived CTL epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas
US9694059B2 (en) Ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases
CN101511384A (zh) 采用GM-CSF和α干扰素制成的并装载热处理的且杀死的癌细胞的树突状细胞
Paczesny et al. Dendritic cells as vectors for immunotherapy of cancer
EP1368061B1 (en) Fusion cells and cytokine compositions for treatment of disease
Kjaergaard et al. Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine
AU2002225990A1 (en) Fusion cells and cytokine compositions for treatment of disease
CN101861163A (zh) 用于治疗黑素瘤的细胞系、含有它们的组合物、制备所述组合物的方法以及治疗方法
JP2006509830A (ja) 癌予防用ハイブリッド細胞ワクチンの調製および投与
EP1130088A1 (en) Hybrid cell vaccines
Weigel et al. Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses
US20050180951A1 (en) Combined immunotherapy of fusion cells and interleukin-12 for treatment of cancer
CN112402596B (zh) 多肽组合物及疫苗
Morse et al. Dendritic cell-based approaches to cancer immunotherapy
Zeng Optimizing immunity against BCR-ABL positive leukemia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100330

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100907